Cross Country Healthcare, Inc. (CCRN) 股票分析

公司概述

Cross Country Healthcare, Inc. operates as a specialized talent management provider within the United States healthcare sector, focusing on the recruitment and deployment of medical personnel for its clients. The company functions within the Medical Care Facilities industry, specifically serving two primary segments: Nurse and Allied Staffing, which covers traditional staffing and recruiting, and Physician Staffing. The organization employs a workforce of 7,890 individuals and holds a total market capitalization of $305.41 million, reflecting its position as a mid-cap entity in the broader healthcare services landscape. With annual revenue reaching $1.05 billion, these valuation metrics indicate that the company possesses significant operational scale but trades at a relatively modest market multiple compared to its revenue generation capabilities, suggesting a focus on volume-based service delivery rather than high-margin profitability.

财务健康

The company reported a Total Revenue of $1.05 billion over the trailing twelve months, yet this revenue figure is offset by a Net Income loss of $94.85 million, highlighting a substantial gap between top-line generation and bottom-line profitability that points to significant cost structures or operational expenses exceeding earnings. Despite the negative net income, the firm maintains a positive EBITDA of $18.53 million, which serves as a critical indicator of its core operational cash generation before interest and tax effects. Furthermore, the company generated Free Cash Flow of $42.77 million, demonstrating that it retains sufficient liquidity from operations to fund capital expenditures and debt obligations without relying heavily on external financing. The Gross Margin stands at 20.3%, while the Operating Margin is negative at -0.6% and the Profit Margin is -9.0%, collectively indicating that while the core service delivery retains some pricing power, fixed overheads and general expenses are currently eroding overall profitability. On the balance sheet, the company holds $108.74 million in cash against a debt load of $2.32 million, resulting in a Debt to Equity ratio of 0.72, which suggests a relatively conservative capital structure with ample liquidity to cover liabilities. This financial resilience is further supported by a Current Ratio of 3.78, signaling strong short-term liquidity and the ability to meet short-term obligations without immediate refinancing pressure. Additionally, the Return on Equity is -25.6% and the Return on Assets is 0.3%, metrics that reveal that management has yet to generate positive returns on shareholder capital or total assets, likely due to the recent period of losses impacting the equity base and asset utilization efficiency.

估值评估

The valuation profile is defined by a Trailing Twelve Months P/E Ratio that is effectively N/A due to negative earnings, contrasted with a Forward P/E of 33.75, which implies that the market expects a significant turnaround in profitability or a re-rating of earnings in the future periods. The Price to Book ratio is listed at 0.93, indicating that the market values the company slightly below its net asset book value, which often suggests a market perception of risk or a discount associated with the current lack of profitability. Alternative valuation metrics such as the Price to Sales ratio of 0.29 and the EV/EBITDA of 10.74 provide context, suggesting the stock is priced at a fraction of its sales volume, though the high forward P/E indicates expectations of future earnings expansion to justify the current share price. The stock has exhibited volatility within a 52-week range bounded by a high of $15.01 and a low of $7.43, with the current trading price positioned significantly below the 52-week high, reflecting recent market pressure or a correction from previous peaks. The Beta is 0.34, which indicates that the stock's price volatility is substantially lower than that of the broader market, suggesting it may act as a defensive position within a portfolio despite its current financial challenges.

Growth & Income

Revenue growth for the trailing twelve months shows a decline of -23.6% year-over-year, while earnings growth is marked as N/A due to the negative net income position, implying that the company is currently in a contractionary phase regarding both top-line sales and profitability. Since the company does not pay a dividend, evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%, all available earnings are theoretically reinvested into operations or retained to bolster the balance sheet rather than distributed to shareholders. The combination of negative revenue growth and a lack of dividend payments constructs a growth and income profile characterized by a transition period where the company prioritizes operational restructuring over shareholder returns or expansion. Overall, the financial data presents a scenario of a company navigating a challenging operational environment with limited income generation for investors, relying instead on its cash reserves and low debt levels to sustain operations during this phase of revenue contraction.